NorthStrive amends license deal with MOA Life Plus for muscle assets

NorthStrive Biosciences Inc., a subsidiary of PMGC Holdings Inc. (NASDAQ: ELAB), signed a third amendment to its licensing agreement with Korean biotechnology company MOA Life Plus Co. Ltd. (KOSDAQ: 142760) for assets EL-32 and EL-22.

The amendment updates timing and development milestones for human clinical development programs of both assets, according to a company statement. The changes align the schedule with research and development and regulatory expectations of both parties.

NorthStrive's lead asset EL-22 uses an engineered probiotic approach to address muscle preservation during weight loss treatments, including GLP-1 receptor agonists. The company focuses on developing aesthetic medicines through its biopharmaceutical operations.

MOA Life Plus operates as a biotechnology company in Korea, focusing on research and development of therapeutic and wellness technologies. The company partners globally for scientific innovation in human and animal health applications.

PMGC Holdings operates as a diversified holding company managing portfolios through acquisitions, investments, and development across multiple industries.

You May Also Be Interested In

• Neuphoria confirms acquisition talks with Scancell Holdings
• Cosmos Health signs Qatar distribution deal with IMC for supplements
• Decoy Therapeutics announces up to $21M private placement